DK513388A - PEPTIDES WITH IMMUNOLOGICAL PROPERTIES RESPONSIBLE FOR HIV-2 VIRUSES, NUCLEOTIDE SEQUENCES CODING FOR SUCH PEPTIDES, ANTIGEN AND IMMUNOGENIC AGENTS CONTAINING SUCH PEPTIDES AND PROCEDURES AND HIV KIT TILT INIT - Google Patents

PEPTIDES WITH IMMUNOLOGICAL PROPERTIES RESPONSIBLE FOR HIV-2 VIRUSES, NUCLEOTIDE SEQUENCES CODING FOR SUCH PEPTIDES, ANTIGEN AND IMMUNOGENIC AGENTS CONTAINING SUCH PEPTIDES AND PROCEDURES AND HIV KIT TILT INIT

Info

Publication number
DK513388A
DK513388A DK513388A DK513388A DK513388A DK 513388 A DK513388 A DK 513388A DK 513388 A DK513388 A DK 513388A DK 513388 A DK513388 A DK 513388A DK 513388 A DK513388 A DK 513388A
Authority
DK
Denmark
Prior art keywords
peptides
hiv
viruses
init
antigen
Prior art date
Application number
DK513388A
Other languages
Danish (da)
Other versions
DK513388D0 (en
DK174705B1 (en
Inventor
Marc Alizon
Luc Montagnier
Denise Guetard
Francois Clavel
Pierre Sonigo
Mireille Guyader
Pierre Tiollais
Lisa Chakrabarti
Ronald Desrosiers
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27251436&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK513388(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/003,764 external-priority patent/US5051496A/en
Priority claimed from FR8701739A external-priority patent/FR2610632B1/en
Priority claimed from FR8705398A external-priority patent/FR2614025B1/en
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of DK513388D0 publication Critical patent/DK513388D0/en
Publication of DK513388A publication Critical patent/DK513388A/en
Priority to DK200201277A priority Critical patent/DK175879B1/en
Application granted granted Critical
Publication of DK174705B1 publication Critical patent/DK174705B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/162—HIV-1, HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Abstract

Peptides having immunological properties in common with those of the peptidic skeleton of peptides of viruses of the family HIV-2, particularly the envelope glycoprotein of HIV-2, characterized in that they have also a peptidic structure in common with the peptidic skeleton of peptides of SIV, particularly the envelope glycoprotein of SIV. The invention also relates to diagnosis compositions capable of detecting an infection due to HIV-2 and to vaccine compositions.
DK198805133A 1987-01-16 1988-09-15 Peptides having immunological properties corresponding to HIV-2 viruses, antigens and immunogenic agents containing such peptides, and methods and kits for an in vitro diagnosis of HIV-2 DK174705B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DK200201277A DK175879B1 (en) 1987-01-16 2002-08-30 NEw peptide(s) with immunological properties of HIV-2 envelope protein - have the structure of simian immune deficiency virus proteins, useful in diagnosis and of vaccine components

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US376487 1982-05-10
US07/003,764 US5051496A (en) 1986-01-22 1987-01-16 Peptides related to human immunodeficiency virus II (HIV-2)
FR8701739 1987-02-11
FR8701739A FR2610632B1 (en) 1987-02-11 1987-02-11 CHARACTERISTIC PEPTIDES OF HUMAN IMMUNODEFICIENCY RETROVIRUSES (HIV VIRUSES) THEIR APPLICATIONS IN THE DIAGNOSIS OF INFECTIONS DUE TO CERTAIN OF THESE VIRUSES AND, IF NECESSARY, IN VACCINATION AGAINST AIDS
FR8705398A FR2614025B1 (en) 1987-04-15 1987-04-15 PEPTIDES LIKELY TO BE RECOGNIZED BY ANTIBODIES INDUCED AGAINST HUMAN IMMUNODEFICIENCY RETROVIRUSES (HIV VIRUSES) THEIR APPLICATIONS IN THE DIAGNOSIS OF INFECTIONS DUE TO CERTAIN VIRUSES AND, IF NECESSARY, IN VACCINATION AGAINST AIDS
FR8705398 1987-04-15
FR8800025 1988-01-05
PCT/FR1988/000025 WO1988005440A1 (en) 1987-01-16 1988-01-15 Peptides having immunological properties 2-hiv-2

Publications (3)

Publication Number Publication Date
DK513388D0 DK513388D0 (en) 1988-09-15
DK513388A true DK513388A (en) 1988-11-16
DK174705B1 DK174705B1 (en) 2003-09-29

Family

ID=27251436

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198805133A DK174705B1 (en) 1987-01-16 1988-09-15 Peptides having immunological properties corresponding to HIV-2 viruses, antigens and immunogenic agents containing such peptides, and methods and kits for an in vitro diagnosis of HIV-2

Country Status (9)

Country Link
EP (1) EP0283327B1 (en)
JP (5) JP2948823B2 (en)
AT (1) ATE154808T1 (en)
AU (1) AU608294B2 (en)
DE (1) DE3855947T2 (en)
DK (1) DK174705B1 (en)
ES (1) ES2104556T3 (en)
GR (1) GR3024823T3 (en)
WO (1) WO1988005440A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8701628D0 (en) * 1987-04-16 1987-04-16 Erling Norrby MEANS OF ANALYSIS MM
AU2914889A (en) * 1987-08-28 1989-04-17 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
US5780038A (en) * 1987-11-16 1998-07-14 Roche Diagnostic Systems, Inc. HIV-2 envelope polypeptides
EP0316695B1 (en) * 1987-11-16 1993-03-31 F. Hoffmann-La Roche Ag Recombinant hiv-2 polypeptides
AU3063389A (en) * 1988-01-08 1989-08-01 Dpz Deutsches Primatenzentrum Gesellschaft M.B.H. Hiv-2-type retroviruses of primates, vaccines, diagnostic and pharmaceutical compositions
FR2632644B1 (en) * 1988-06-10 1994-11-04 Pasteur Institut PRECURSOR ANTIGENS OF HUMAN HIV-2 RETROVIRUS ENVELOPE GLYCOPROTEINS AND ANTIGENS HAVING AN IMMUNOLOGICAL PARENT TO THESE LATTERS. PREPARATION OF THESE ANTIGENS. APPLICATION TO DIAGNOSIS
JP3093763B2 (en) * 1988-06-09 2000-10-03 インスティチュート・パスツール Precursor antigen of envelope glycoprotein of human retrovirus HIV-2, antigen having immunological homology thereto, method for preparing these antigens and application to diagnosis
DE346022T1 (en) * 1988-06-10 1990-05-23 Medical Research Council, London, Gb PEPTIDE FRAGMENTS OF HIV.
IL90553A0 (en) * 1988-06-13 1990-01-18 Us Health Protein and coding sequence for detection and differentiation of siv and hiv-2 group of viruses
FR2635532B1 (en) * 1988-07-29 1992-05-22 Pasteur Institut HYBRID RECOMBINANT HBSAG PARTICLES: MORPHOLOGICAL CHARACTERISTICS OF THE HBSAG ANTIGEN CONTAINING 1 IMMUNOGENIC SEQUENCE INDUCING NEUTRALIZING ANTIBODIES DIRECTED AGAINST HIV OR LIKELY TO BE RECOGNIZED BY SUCH ANTIBODIES; NUCLEOTIDE SEQUENCES ENCODING FOR SUCH PARTICLES; VACCINES CONTAINING THEM
EP0362927A3 (en) * 1988-10-06 1990-11-14 Akzo N.V. Synthetic polypeptides immunochemically reactive with hiv antibodies
CA2003383A1 (en) * 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
US5260189A (en) * 1988-12-20 1993-11-09 Immunodiagnostics, Inc. Synthetic HIV-like peptides their compositions and uses
FR2646854A1 (en) * 1989-05-12 1990-11-16 Pasteur Institut Antigens of the envelope transmembrane glycoprotein of a HIV-2 type human retrovirus, antigens exhibiting an immunological relationship with them
SG48125A1 (en) * 1989-05-12 1998-04-17 Pasteur Institut Antigenes of the envelope transmembrance glcoprotein of a human retrovirus of the hiv-2 type and antigens presenting with them an immunological relationship
ES2110283T3 (en) * 1989-05-31 1998-02-01 Pasteur Institut ANTIBODY PROTEINS AND GLYCOPROTEINS OF HIV-2 EHO RETROVIRUSES DIRECTED AGAINST THEM - APPLICATION FOR DIAGNOSIS.
FR2647810B1 (en) * 1989-06-02 1994-07-22 Pasteur Institut OLIGONUCLEOTIDE PRIMERS FOR THE AMPLIFICATION OF THE GENOME OF HIV-2 AND SIV RETROVIRUSES, AND THEIR APPLICATIONS TO THE IN VITRO DIAGNOSIS OF INFECTIONS DUE TO THESE VIRUSES
US7022814B1 (en) 1992-01-21 2006-04-04 Institut Pasteur And Institut National De La Sante Et De La Recherche Medicale Nucleotide sequences derived from the genome of retroviruses of the HIV-1, HIV-2 and SIV type, and their uses in particular for the amplification of the genomes of these retroviruses and for the in vitro diagnosis of the diseases due to these viruses
FR2647809B1 (en) * 1989-06-02 1991-09-20 Pasteur Institut OLIGONUCLEOTIDE PRIMERS FOR THE AMPLIFICATION OF THE GENOME OF HIV-1, HIV-2 AND SIV RETROVIRUSES AND THEIR APPLICATIONS TO IN VITRO DIAGNOSIS OF INFECTIONS DUE TO THESE VIRUSES
CA2585164C (en) * 1989-06-02 2010-02-02 Institut Pasteur Nucleotides sequences derived from the genome of type hiv-1, hiv-2 and siv retroviruses, and their applications especially for the amplification the genomes of these retroviruses and for in vitro diagnosis of infections due to these viruses
DE3934366A1 (en) * 1989-10-14 1991-04-18 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus VACCINE FOR PROTECTION AGAINST HIV VIRUS INFECTIONS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A DIAGNOSTIC AND IMMUNOTHERAPEUTIC
US6248574B1 (en) * 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
FR2657016B1 (en) * 1990-01-16 1995-08-25 Clonatec Sa PEPTIDES DERIVED FROM THE GLYCOPROTEIN ENVELOPE OF THE HIV-2 VIRUS, THEIR APPLICATIONS FOR THE DETECTION OF AN INFECTION DUE TO THIS VIRUS AND FOR VACCINATION AGAINST AIDS.
ATE164853T1 (en) * 1990-01-16 1998-04-15 Orgenics Ltd PEPTIDES DERIVED FROM VIRUS HIV ENVEL GLYCOPROTEINS, THEIR USE FOR DETECTING INFECTION OF THESE VIRUSES AND FOR VACCINATION AGAINST AIDS
DE4002636A1 (en) * 1990-01-30 1991-08-01 Boehringer Mannheim Gmbh EXPRESSION OF HIV1 AND 2 POLYPEPTIDES AND THEIR USE
WO1992021377A1 (en) * 1991-06-03 1992-12-10 Syntello Inc. Peptides for use in induction of t cell activation against hiv-1
EP0726962B1 (en) 1991-12-23 2006-06-07 Chiron Corporation Sets of HIV probes for use in solution phase sandwich hybridisation assays
JPH0748276A (en) * 1992-03-26 1995-02-21 Inmeru:Kk Preventing vaccine for hiv infectious disease and production thereof
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
DE4405810A1 (en) 1994-02-23 1995-08-24 Behringwerke Ag Peptides derived from a retrovirus from the HIV group and their use
ATE467690T1 (en) * 1997-08-01 2010-05-15 Bio Rad Laboratories SYNTHETIC ANTIGEN FOR DETECTING HIV IMMUNOREACTIVE ANTIBODIES
DE19908766C2 (en) * 1999-02-19 2001-02-15 Ulrich Schubert Use of synthetic Vpr peptides of the human immunodeficiency virus type 1 (HIV-1) for the development of therapeutic and diagnostic reagents
CA2562385A1 (en) * 2004-04-09 2005-10-20 University Of Manitoba Identification of the precise amino acid sequence of the epitope recognized by the potent neutralizing human anti-hiv-1 monoclonal antibody igg1b12
EP2420248A1 (en) * 2004-08-17 2012-02-22 Institut Gustave Roussy Mutated HIV NEF for modulating immunity
WO2007084021A2 (en) * 2006-01-17 2007-07-26 Instituto De Medicina Molecular Compositions and methods for diagnosing hiv-2 infection

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3583293D1 (en) * 1984-10-18 1991-07-25 Pasteur Institut LYMPHADENOPATHY-ASSOCIATED SHELL ANTIGENS AND THEIR USE.
AU600658B2 (en) * 1984-12-24 1990-08-23 Genentech Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
DK171119B1 (en) * 1985-04-19 1996-06-17 Hoffmann La Roche AIDS virus envelope protein, expression vector carrying the envelope protein, transformants transformed with the expression vector, method of producing the virus envelope protein, method of detecting AIDS antibodies, method of determining AIDS virus, vaccine against AIDS, antibodies against the virus envelope protein and use of it to prepare a vaccine and for testing
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
DE3533440A1 (en) * 1985-09-19 1987-03-26 Hoechst Ag N-SUBSTITUTED 3,4,5,6-TETRAHYDROPHTHALIMIDES, METHODS FOR THEIR PRODUCTION AND THEIR USE IN PLANT PROTECTION
NZ217645A (en) * 1985-09-25 1991-11-26 Oncogen Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations
EP0239425B1 (en) * 1986-01-22 1989-11-02 Institut Pasteur Retrovirus of the type hiv-2 capable of inducing aids, and the antigenic and nucleic acid components thereof
FR2593189B1 (en) * 1986-01-22 1989-10-20 Pasteur Institut NEW RETROVIRUS THAT MAY CAUSE AIDS, ANTIGENS OBTAINED FROM THIS RETROVIRUS AND CORRESPONDING ANTIBODIES AND THEIR APPLICATIONS TO AIDS DIAGNOSIS
EP0269520A3 (en) * 1986-11-21 1988-08-24 Institut Pasteur Retrovirus of the type hiv-2, susceptible to provoke aids, and its antigenic and nucleic-acid constituents
JP3105581B2 (en) * 1991-07-03 2000-11-06 内橋エステック株式会社 Planar temperature fuse
JPH0833969A (en) * 1994-07-22 1996-02-06 Toyota Motor Corp Pressurized casting method

Also Published As

Publication number Publication date
AU1225088A (en) 1988-08-10
EP0283327A2 (en) 1988-09-21
DK513388D0 (en) 1988-09-15
DE3855947T2 (en) 1997-12-11
DE3855947D1 (en) 1997-07-31
ATE154808T1 (en) 1997-07-15
JPH07300498A (en) 1995-11-14
JP2004002421A (en) 2004-01-08
JP2002030099A (en) 2002-01-29
EP0283327A3 (en) 1989-01-04
EP0283327B1 (en) 1997-06-25
WO1988005440A1 (en) 1988-07-28
JPH01502119A (en) 1989-07-27
GR3024823T3 (en) 1998-01-30
DK174705B1 (en) 2003-09-29
ES2104556T3 (en) 1997-10-16
AU608294B2 (en) 1991-03-28
JP2948823B2 (en) 1999-09-13
JP2862810B2 (en) 1999-03-03
JPH11322792A (en) 1999-11-24

Similar Documents

Publication Publication Date Title
DK513388D0 (en) PEPTIDES WITH IMMUNOLOGICAL PROPERTIES RESPONSIBLE FOR HIV-2 VIRUSES, NUCLEOTIDE SEQUENCES CODING FOR SUCH PEPTIDES, ANTIGEN AND IMMUNOGENIC AGENTS CONTAINING SUCH PEPTIDES AND PROCEDURES AND HIV KIT TILT INIT
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
ES2061500T5 (en) DIAGNOSIS AND VACCINES OF DELTA HEPATITIS, ITS PREPARATION AND USE.
DK33190A (en) HIV-3 RETROVIRUS AND ITS USE
KR950032278A (en) Peptides Derived from Retroviruses of the Human Immunodeficiency Virus Group and Uses thereof
ES2009350A6 (en) Expression and purification of an HTLV-III gag/env gene protein
ES2013346A6 (en) Dna sequences, recombinant dna molecules and processes for producing soluble t4 proteins.
DK1278534T3 (en) Methods and compositions for attenuating the multiplication of HIV-1
DK637988A (en) RECOMBINANT POLYPEPTIDES
DK373489D0 (en) RECOMBINANT HYBRID PARTICLES WITH MORPHOLOGICAL PROPERTIES RESPONSIBLE FOR THE ANTI-ANGLE CASE AND INCLUDING AN IMMUNOGENIC SEQUENCE INPUTING NEUTRALIZING ANTIBODIES AGAINST ANTI-RETROVIRUS ANTIVES, OR SUCH CAN BE GIVEN
EP0293792A3 (en) Human immunodeficiency virus gag-encoded proteins
EP0250128A3 (en) Novel virus isolated from patients with aids
DK284389D0 (en) PRECURSOR ANTIGENES
ATE417108T1 (en) HIV-2 AND SIV-1 NUCLEOTIDE SEQUENCES
PT86752A (en) NEw peptide(s) with immunological properties of HIV-2 envelope protein - have the structure of simian immune deficiency virus proteins, useful in diagnosis and of vaccine components

Legal Events

Date Code Title Description
PUP Patent expired